IGF1 and cancer: Therefore, metformin treatment-related decrease in circulating insulin levels correlates to the ‘indirect’ anti-cancer/anti-tumor effects of metformin via the inhibition of the mitogenic and pro-angiogenic signaling mechanisms which are otherwise activated by insulin and IGF1 [51,52,80].